We thank Gang Lv and colleagues for the response to our study.1 We agree that minimal residual disease (MRD) monitoring could help to optimise the treatment of mantle-cell lymphoma with ibrutinib and other Bruton tyrosine kinase (BTK) inhibitors. However, no study comparing outcomes of continuous use of BTK inhibitors versus an MRD-driven approach has yet been reported.
Simon Rule
As seen in:
Nature,
The Lancet,
HemOnc Today,
CURE Magazine,
ONCOLOGY journal,
OncLive,
Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Simon Rule
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
To the Editor: B-cell receptor (BCR) signaling pathway inhibitors (including Bruton’s tyrosine kinase [BTK] inhibitors, and phosphatidylinositol-3 kinase inhibitors [PI3Ki]) have shown clinical efficacy in non-Hodgkin lymphoma (NHL). However, responses to these agents have been limited in depth and duration. This may be due to resistance to PI3Kδ and BTK inhibitors as monotherapy [1,2,3,4,5]. The emergence of resistant clones may be addressed by combining these 2 classes of drugs.
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
Summary Background Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic. Acalabrutinib is a selective, potent Bruton tyrosine-kinase inhibitor. The aim of this trial was to evaluate the activity and safety of acalabrutinib in patients with Waldenström macroglobulinemia.
Simon Rule, MD, PhD, on Long-Term Outcomes with Ibrutinib Versus Prior Treatment Regimens
January 2, 2020 At the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, in Orlando, Florida, Simon Rule, MD, PhD talked about the findings from up to 7.5 years of extended follow up of patients receiving ibrutinib (Imbruvica) for relapsed/refractory mantle cell lymphoma (MCL). Transcription So, what we did was just further follow up a group of patients that we've been looking at for a while now.
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
To the Editor: Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor signaling pathway [1, 2]. Remarkably, approximately two thirds of patients with relapsed/refractory (R/R) MCL treated with ibrutinib, the first-in-class BTK inhibitor, achieve a durable response [3,4,5].
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
To the Editor: Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1,2,3,4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5].
Bureaucracy is strangling clinical research
Simon Rule, professor of haematology1, Steven LeGouill, professor of haematology2 1Plymouth University Peninsula Schools of Medicine and Dentistry, UK 2University of Nantes, France simon.rule{at}nhs.net Legislation has not appreciably changed since 2001, but those administering it or working within it are producing more and more bureaucratic demands Clinical research is fundamental to the advancement of medical practice and improving outcomes for patients.
Bortezomib-based chemotherapy in mantle cell lymphoma
Management of patients with newly diagnosed mantle cell lymphoma is fairly well established. For younger patients, treatment involves high-dose cytarabine-based chemotherapy, which is usually consolidated with stem-cell transplantation and rituximab maintenance therapy.
Long-term ibrutinib appears effective in lymphoma subtype
ATLANTA — Long-term follow-up demonstrated that more than a quarter of patients with relapsed/refractory mantle cell lymphoma treated with ibrutinib remained progression free, and approximately half remained alive, at 3 years, according to findings presented at the ASH Annual Meeting and Exposition.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Summary Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity. Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Simon
Contact Simon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack